Zogenix nets $60.7m for Zohydro and Sumavel plus debt repayment
This article was originally published in Scrip
Zogenix, a pharmaceutical company focused on central nervous system disorders and pain, priced 32.5 million shares of common stock plus warrants at $2 per share on 24 July for net proceeds of $60.7 million to finance operations related to the approval and commercialization of the oral extended-release hydrocodone therapy Zohydro, among other expenses.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.